A citation-based method for searching scientific literature

Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Terrance D Barrett, Michele Weidner-Wells, Hsiaowei Deng, David R Matthews, Bruce Neal. Lancet Diabetes Endocrinol 2018
Times Cited: 227



Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Silvio E Inzucchi. N Engl J Med 2015
Times Cited: 4839




List of shared articles



Times cited

A Pilot Study Embedding Clinical Pharmacists Within an Interprofessional Nephrology Clinic for the Initiation and Monitoring of Empagliflozin in Diabetic Kidney Disease.
Laura K Triantafylidis, Chelsea E Hawley, Christopher Fagbote, Jiahua Li, Nicole Genovese, Julie M Paik. J Pharm Pract 2021
5

Blood pressure after treatment with sodium-glucose cotransporter 2 inhibitors influences renal composite outcome: Analysis using propensity score-matched models.
Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Takayuki Furuki, Hiroyuki Sakai, Tomoya Umezono, Shun Ito, Daisuke Suzuki, Hiroshi Takeda, Fuyuki Minagawa,[...]. J Diabetes Investig 2021
1

Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Nobumichi Saito, Tomohiko Kanaoka, Hiroyuki Sakai, Takayuki Furuki, Tomoya Umezono, Shun Ito, Daisuke Suzuki,[...]. Diabetes Technol Ther 2021
1

Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors.
Davide Margonato, Giuseppe Galati, Simone Mazzetti, Rosa Cannistraci, Gianluca Perseghin, Alberto Margonato, Andrea Mortara. Heart Fail Rev 2021
5


Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Jaime Blais, Qiang Li, Meg J Jardine,[...]. Am J Kidney Dis 2021
3

An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials.
Jie Yu, Zien Zhou, Kenneth W Mahaffey, David R Matthews, Brendon L Neuen, Hiddo J L Heerspink, Meg J Jardine, JingWei Li, Vlado Perkovic, Bruce Neal,[...]. Int J Cardiol 2021
3

TaleNeprilysin and Neprilysin inhibition in chronic kidney disease.
Parminder K Judge, Richard Haynes. Curr Opin Nephrol Hypertens 2021
0

Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations.
Chin Meng Khoo, Chaicharn Deerochanawong, Siew Pheng Chan, Bien Matawaran, Wayne Huey-Herng Sheu, Juliana Chan, Ambrish Mithal, Andrea Luk, Ketut Suastika, Kun-Ho Yoon,[...]. Diabetes Obes Metab 2021
2


Dapagliflozin Does Not Affect Short-Term Blood Pressure Variability in Patients With Type 2 Diabetes Mellitus.
Eirini Papadopoulou, Marieta P Theodorakopoulou, Charalampos Loutradis, Georgios Tzanis, Glykeria Tzatzagou, Kalliopi Kotsa, Ioanna Zografou, Apostolos Tsapas, Asterios Karagiannis, Pantelis Sarafidis. Am J Hypertens 2021
0

Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors.
Rosalie A Scholtes, Michaël J B van Baar, Megan D Kok, Petter Bjornstad, David Z I Cherney, Jaap A Joles, Daniël H van Raalte. Nephrology (Carlton) 2021
2

The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial.
Phil McEwan, Angharad R Morgan, Rebecca Boyce, Klas Bergenheim, Ingrid A M Gause-Nilsson, Deepak L Bhatt, Lawrence A Leiter, Peter A Johansson, Ofri Mosenzon, Avivit Cahn,[...]. Diabetes Obes Metab 2021
4

Sodium-glucose cotransporter 2 inhibitor-induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease: A propensity score-matched model analysis in Japan.
Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Takayuki Furuki, Hiroyuki Sakai, Kazuyoshi Sato, Masaaki Miyakawa, Kouichi Tamura, Akira Kanamori. J Diabetes Investig 2021
0

Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials.
Ravi B Patel, Jozine M Ter Maaten, João Pedro Ferreira, Finnian R McCausland, Sanjiv J Shah, Patrick Rossignol, Scott D Solomon, Muthiah Vaduganathan, Milton Packer, Aliza Thompson,[...]. Circulation 2021
2

Sodium-glucose cotransporter 2 inhibitors in type 2 diabetes patients with renal function impairment slow the annual renal function decline, in a real clinical practice.
Taro Hirai, Munehiro Kitada, Itaru Monno, Erina Oda, Yoshihiro Hayashi, Keiji Shimada, Yuta Takagaki, Yoshio Ogura, Mizue Fujii, Kazunori Konishi,[...]. J Diabetes Investig 2021
2

Canagliflozin: metabolic, cardiovascular and renal protection.
Vivencio Barrios, Carlos Escobar. Future Cardiol 2021
1

Using machine learning to identify diabetes patients with canagliflozin prescriptions at high-risk of lower extremity amputation using real-world data.
Lanting Yang, Nico Gabriel, Inmaculada Hernandez, Almut G Winterstein, Jingchuan Guo. Pharmacoepidemiol Drug Saf 2021
0

Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58.
Avivit Cahn, Itamar Raz, Lawrence A Leiter, Ofri Mosenzon, Sabina A Murphy, Erica L Goodrich, Ilan Yanuv, Aliza Rozenberg, Deepak L Bhatt, Darren K McGuire,[...]. Diabetes Care 2021
2

Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin.
Ricardo Fontes-Carvalho, Diogo Santos-Ferreira, Itamar Raz, Nikolaus Marx, Frank Ruschitzka, Francesco Cosentino. Eur J Prev Cardiol 2021
0

GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis.
Thomas Karagiannis, Apostolos Tsapas, Eleni Athanasiadou, Ioannis Avgerinos, Aris Liakos, David R Matthews, Eleni Bekiari. Diabetes Res Clin Pract 2021
2

Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis.
Takashi Kadowaki, Fumiko Yamamoto, Yusuke Taneda, Yusuke Naito, Douglas Clark, Søren S Lund, Tomoo Okamura, Kohei Kaku. Expert Opin Drug Saf 2021
0


Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility.
Giulia Ferrannini, Gianluigi Savarese, Lars Rydén. Diabetes Res Clin Pract 2021
0

Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Thomas A Zelniker, Itamar Raz, Ofri Mosenzon, Jamie P Dwyer, Hiddo H J L Heerspink, Avivit Cahn, Erica L Goodrich, Kyungah Im, Deepak L Bhatt, Lawrence A Leiter,[...]. JAMA Cardiol 2021
0


From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes.
Ofri Mosenzon, Stefano Del Prato, Meir Schechter, Lawrence A Leiter, Antonio Ceriello, Ralph A DeFronzo, Itamar Raz. Cardiovasc Diabetol 2021
1

Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease.
Alberto Ortiz, Charles J Ferro, Olga Balafa, Michel Burnier, Robert Ekart, Jean-Michel Halimi, Reinhold Kreutz, Patrick B Mark, Alexandre Persu, Patrick Rossignol,[...]. Nephrol Dial Transplant 2021
1

Sodium-glucose co-transporter-2 inhibitor-associated euglycemic diabetic ketoacidosis that prompted the diagnosis of fulminant type-1 diabetes: A case report.
Taro Yasuma, Yuko Okano, Soichiro Tanaka, Kota Nishihama, Kazuhito Eguchi, Chisa Inoue, Kanako Maki, Akihiro Uchida, Mei Uemura, Toshinari Suzuki,[...]. World J Clin Cases 2021
0

Recent advances in new-onset diabetes mellitus after kidney transplantation.
Tess Montada-Atin, G V Ramesh Prasad. World J Diabetes 2021
0

Recent advances in pharmacological treatment of heart failure.
Massimo Iacoviello, Alberto Palazzuoli, Edoardo Gronda. Eur J Clin Invest 2021
0


Chronic Kidney Disease as a Systemic Inflammatory Syndrome: Update on Mechanisms Involved and Potential Treatment.
Francesca Tinti, Silvia Lai, Annalisa Noce, Silverio Rotondi, Giulia Marrone, Sandro Mazzaferro, Nicola Di Daniele, Anna Paola Mitterhofer. Life (Basel) 2021
1

Contemporary Medical Management of Peripheral Artery Disease.
Marc P Bonaca, Naomi M Hamburg, Mark A Creager. Circ Res 2021
1

Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials.
David Z I Cherney, Samuel Dagogo-Jack, Darren K McGuire, Francesco Cosentino, Richard Pratley, Weichung J Shih, Robert Frederich, Mario Maldonado, Jie Liu, Shuai Wang,[...]. Clin Cardiol 2021
1

Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis.
William Hinton, Michael D Feher, Neil Munro, Mark Joy, Simon de Lusignan. Cardiovasc Diabetol 2021
0

Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors.
William G Herrington, Gianluigi Savarese, Richard Haynes, Nikolaus Marx, Linda Mellbin, Lars H Lund, Paul Dendale, Petar Seferovic, Giuseppe Rosano, Natalie Staplin,[...]. Eur J Heart Fail 2021
0

Empagliflozin confers reno-protection in acute myocardial infarction and type 2 diabetes mellitus.
Kosuke Mozawa, Yoshiaki Kubota, Yu Hoshika, Shuhei Tara, Yukichi Tokita, Kenji Yodogawa, Yu-Ki Iwasaki, Takeshi Yamamoto, Hitoshi Takano, Yayoi Tsukada,[...]. ESC Heart Fail 2021
0

Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS Program.
Katherine M Wang, JingWei Li, Vivek Bhalla, Meg J Jardine, Bruce Neal, Dick de Zeeuw, Greg Fulcher, Vlado Perkovic, Kenneth W Mahaffey, Tara I Chang. Endocrinol Diabetes Metab 2021
0

Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations.
Dimitrios A Vrachatis, Konstantinos A Papathanasiou, Konstantinos E Iliodromitis, Sotiria G Giotaki, Charalampos Kossyvakis, Konstantinos Raisakis, Andreas Kaoukis, Vaia Lambadiari, Dimitrios Avramides, Bernhard Reimers,[...]. Drugs 2021
0

Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial.
Abhinav Sharma, Anne Pernille Ofstad, Tariq Ahmad, Bernard Zinman, Isabella Zwiener, David Fitchett, Christoph Wanner, Jyothis T George, Stefan Hantel, Nihar Desai,[...]. JACC Heart Fail 2021
0

Influence of SGLT2 Inhibitor Treatment on Urine Antioxidant Status in Type 2 Diabetic Patients: A Pilot Study.
Diana Nabrdalik-Leśniak, Katarzyna Nabrdalik, Katarzyna Sedlaczek, Patryk Główczyński, Hanna Kwiendacz, Tomasz Sawczyn, Weronika Hajzler, Karolina Drożdż, Mirela Hendel, Krzysztof Irlik,[...]. Oxid Med Cell Longev 2021
0

Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence.
Meir Schechter, Cheli Melzer-Cohen, Aliza Rozenberg, Ilan Yanuv, Gabriel Chodick, Avraham Karasik, Mikhail Kosiborod, Ofri Mosenzon. Cardiovasc Diabetol 2021
0


Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials.
José Silva-Cardoso, Omar Sheikh, Mouhamed Nashawi, Son Pham, Kelly M Gallegos, Laith R Dinkha, Robert J Chilton. J Diabetes 2020
3

Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program.
Toshiaki Ohkuma, Luc Van Gaal, Wayne Shaw, Kenneth W Mahaffey, Dick de Zeeuw, David R Matthews, Vlado Perkovic, Bruce Neal. Diabetes Obes Metab 2020
8